Latest operating income for BXRX: $-21M.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2023
Trailing 12 months ending Sep 30, 2023
Baudax Bio (BXRX) currently reports a operating income of $-21M as of September 2023. That compares with $-41M in the prior-year period — up 48.2% year over year. Use the charts on this page to explore Baudax Bio's operating income history and peer comparisons.
Baudax Bio's operating income increased from $-41M to $-21M — a 48.2% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Baudax Bio reported $-21M in operating income as of September 2023. That compares with $-41M in the prior-year period — up 48.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current operating income of $-21M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Baudax Bio, and consider following BXRX for alerts when major investors trade the stock.
Baudax Bio is classified in the Healthcare sector. On operating income, it currently shows $-21M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BXRX with unrelated industries.